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Leslie A Crews1,2, Qingfei Jiang1,2, Maria A Zipeto1,2, Elisa Lazzari1,2,3, Angela C Court1,2, Shawn Ali1,2,
Christian L Barrett4, Kelly A Frazer4 and Catriona HM Jamieson1,2*Abstract
Background: Deregulation of RNA editing by adenosine deaminases acting on dsRNA (ADARs) has been implicated in
the progression of diverse human cancers including hematopoietic malignancies such as chronic myeloid leukemia
(CML). Inflammation-associated activation of ADAR1 occurs in leukemia stem cells specifically in the advanced, often
drug-resistant stage of CML known as blast crisis. However, detection of cancer stem cell-associated RNA editing by RNA
sequencing in these rare cell populations can be technically challenging, costly and requires PCR validation. The
objectives of this study were to validate RNA editing of a subset of cancer stem cell-associated transcripts, and to
develop a quantitative RNA editing fingerprint assay for rapid detection of aberrant RNA editing in human malignancies.
Methods: To facilitate quantification of cancer stem cell-associated RNA editing in exons and intronic or 3'UTR
primate-specific Alu sequences using a sensitive, cost-effective method, we established an in vitro RNA editing model
and developed a sensitive RNA editing fingerprint assay that employs a site-specific quantitative PCR (RESSq-PCR)
strategy. This assay was validated in a stably-transduced human leukemia cell line, lentiviral-ADAR1 transduced primary
hematopoietic stem and progenitor cells, and in primary human chronic myeloid leukemia stem cells.
Results: In lentiviral ADAR1-expressing cells, increased RNA editing of MDM2, APOBEC3D, GLI1 and AZIN1 transcripts
was detected by RESSq-PCR with improved sensitivity over sequencing chromatogram analysis. This method accurately
detected cancer stem cell-associated RNA editing in primary chronic myeloid leukemia samples, establishing a cancer
stem cell-specific RNA editing fingerprint of leukemic transformation that will support clinical development of novel
diagnostic tools to predict and prevent cancer progression.
Conclusions: RNA editing quantification enables rapid detection of malignant progenitors signifying cancer
progression and therapeutic resistance, and will aid future RNA editing inhibitor development efforts.
Keywords: Cancer stem cells, Leukemia stem cells, RNA editing, Biomarkers, Leukemia, ADAR1Background
Dormant cancer stem cells (CSCs) are primary arbiters of
cancer progression and a major focus of targeted therapy
development efforts. Deregulation of RNA editing by ad-
enosine deaminases acting on double-stranded (ds) RNA
(ADARs) has been implicated in the progression of diverse
human malignancies, including chronic and acute forms
of leukemia [1-3], lobular breast cancer [4], hepatocellular
carcinoma [5,6], and esophageal squamous cell carcinoma
[7]. Recent evidence also supports a role for aberrant* Correspondence: cjamieson@ucsd.edu
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unless otherwise stated.RNA editing in malignant reprogramming of progenitor
cells into self-renewing CSCs, suggesting that ADARs and
their target substrates may be harbingers of cancer pro-
gression [1,4,5].
Of particular relevance to the pathogenesis of human
disease, over 90% of RNA editing occurs in primate-
specific Alu sequences that form dsRNA secondary struc-
tures [8], often within non-coding regions such as introns
and 3′UTRs [9]. Most RNA editing is carried out by
ADAR-mediated C6 deamination of adenosines (A) to
inosines (I) [10]. The ADAR family consists of three mem-
bers, ADAR1 (ADAR), ADAR2 (ADARB1), and ADAR3
(ADARB2). In mouse hematopoietic development, ADAR1
plays a key role in hematopoietic stem cell (HSC) survivalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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primary RNA editase expressed in human hematopoietic
stem and progenitor cells [1]. At the transcript level, RNA
editing can affect mRNA stability, localization, nuclear re-
tention, and alternative splicing [14-16]. While RNA editing
targets are relatively conserved in normal tissues [17],
CSC-associated editing changes in response to malig-
nant microenvironments could dramatically alter gene
product stability and function. Additionally, aberrant
RNA editing may drive stem cell regulatory transcript
recoding and microRNA deregulation [18] leading to
therapeutic resistance.
Advances in next-generation sequencing technologies
and bioinformatics tools have led to the identification of
hundreds of thousands of RNA editing sites throughout
the human transcriptome [19,20], the majority of which
are localized to hyper-edited regions [21]. With the
availability of such massive new datasets, it is now crit-
ical to apply this knowledge to mine new and existing
RNA-sequencing (RNA-seq) datasets of human tissues,
to identify disease-relevant RNA editing loci. Previously,
we found that human leukemia stem cells (LSC) from
patients with blast crisis (BC) chronic myeloid leukemia
(CML) harbored increased expression of ADAR1 com-
pared with normal and chronic phase (CP) progenitors
[1]. Since RNA editing may be selectively inhibited, it is of
great clinical relevance to develop diagnostic and prognostic
tools capable of accurately detecting fingerprints of aberrant
RNA editing activity signifying cancer progression and
therapeutic resistance. However, the functional role of RNA
editing of individual transcripts, and its role in cancer pro-
gression and drug resistance, has not been widely addressed
due to a lack of tools to quantify functionally relevant RNA
editing events in a sensitive, cost-effective manner. Trad-
itional Sanger sequencing is not sufficiently sensitive to de-
tect editing events in rare stem cell regulatory transcripts,
and transcriptome-wide profiling of RNA editing can be
costly, technically challenging [22], and analysis requires
expertise in specialized bioinformatics methods.
To address these challenges, we developed and ap-
plied a straightforward, clinically amenable assay to val-
idate and quantify RNA recoding in stem cell regulatory
transcripts identified through whole transcriptome
RNA-seq analysis of purified primary LSC [1]. A site-
specific RNA editing fingerprint of leukemic progres-
sion was validated in a lentiviral-ADAR1 model, and a
sensitive RNA editing site-specific quantitative RT-PCR
(RESSq-PCR) assay was devised to detect aberrant RNA
editing in three different dsRNA contexts (3′UTRs, in-
tronic Alu sequences, and coding exons). This clinically
relevant assay sets the stage for RNA editing biomarker
detection in diagnostic and prognostic assays for clinical
use and as screening tools for identifying pharmaco-
logical modulators of RNA editing.Methods
Primary samples and tissue processing
A large collection of leukemia patient samples and normal
age-matched control bone marrow samples were obtained
from consenting patients in accordance with Institutional
Review Board approved protocols at UCSD and the
University of Toronto (Additional file 1: Table S1). Peri-
pheral blood or bone marrow samples were processed by
Ficoll density centrifugation and viable cells stored in liquid
nitrogen. Normal peripheral blood mononuclear cells
(MNC) were obtained from AllCells (Alameda, CA). Mono-
nuclear cells from control or CML patient samples were
then further purified by magnetic bead separation of CD34+
cells (MACS; Miltenyi, Bergisch Gladbach, Germany) for
subsequent FACS-purification of hematopoietic progenitor
cells (CD34+CD38+Lin-) that represent the LSC fraction in
BC CML [23]. Datasets from previous RNA-seq analyses of
purified CML LSC are available through the NIH Sequence
Read Archive (SRA), accession ID SRP028528.
Primary CSC purification
For primary patient-derived LSC purification, CD34-
selected cells were stained with fluorescent antibodies
against human CD34, CD38, lineage markers (cocktail, all
antibodies from BD Biosciences, San Diego, CA) and pro-
pidium iodide as previously described [1,23,24]. Following
staining, cells were analyzed and sorted using a FACS Aria
II (Sanford Consortium Stem Cell Core Facility), and
hematopoietic progenitor (CD34+CD38+Lin-) populations
were isolated. Freshly-sorted cells were collected in lysis
buffer (Qiagen, Germantown, MD) for RNA extraction
followed by RNA-seq or qRT-PCR analyses as previously
described [1].
High-fidelity PCR and Sanger sequencing analysis
For PCR and targeted Sanger sequencing analysis, 1-2 μL
of first-strand cDNA templates were prepared for PCR in
25-50 μL reaction volumes using the high-fidelity KOD
Hot Start DNA Polymerase kit according to the manufac-
turer’s instructions (EMD Millipore, Temecula, CA).
“Outer” primers (Additional file 2: Table S2) used for se-
quencing produce predicted amplicons of approximately
150-250 nucleotides in length, and flank each editing site
with approximately 50-100 bp on either side of the editing
site to facilitate successful sequencing analysis. PCR cyc-
ling conditions were as follows: 95°C for 2 minutes,
followed by 35 cycles of 95°C for 20 seconds, 62°C for
10 seconds and 70°C for 10 seconds, with a final extension
step of 70°C for 30 seconds. Production of amplicons of
the predicted size was verified for each outer primer set by
DNA gel electrophoresis using 10-20 μL of the completed
reaction mixture separated on 2% agarose gels containing
ethidium bromide and visualized under UV light. Then,
15 μL of each reaction was processed within 24 hrs for
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3730 × l DNA Sequencers (Eton Bioscience, San Diego,
CA). Sanger sequencing was carried out using the reverse
outer primer used for PCR amplification, so edited loci are
identified in the reverse complementary sequence as T/C
nucleotides, except in cases where the gene products are
transcribed from the reverse strand. Sequence chromato-
grams were analyzed using 4Peaks (by A. Griekspoor and
Tom Groothuis, www.nucleobytes.com) and peak heights
calculated using ImageJ (NIH). For RNA editing analysis
of sequencing chromatograms, ratios of edited/WT peaks
were calculated using the raw peak amplitude of each
sequence trace.
Cell lines and culture conditions
K562 cells (ATCC, Manassas, VA) were maintained in
complete medium containing DMEM (Life Technologies,
Carlsbad, CA), 10% fetal bovine serum (FBS), 1% Gluta-
max (Life Technologies), and 1% penicillin-streptomycin
(Life Technologies). Parental cell lines and stably-
transduced lines were authenticated as K562 by rou-
tine qRT-PCR analysis of BCR-ABL transcript levels
[1]. Mouse bone marrow stromal cell lines (SL and
M2) expressing human interleukin-3 (IL-3), stem cell
factor (SCF) and granulocyte-colony stimulating factor
(G-CSF), which support erythroid and myeloid cell ex-
pansion and differentiation, were maintained under
standard culture conditions, as previously described
[25]. Briefly, SL cells were grown in complete medium
containing DMEM, 10% FBS, 1% Glutamax, and 1%
penicillin-streptomycin, while M2 cells were grown in
complete medium containing RPMI, 10% FBS, 1% Glu-
tamax, and 1% penicillin-streptomycin (all from Life
Technologies). Every four passages, cells were selected
by addition of G418 and hygromycin to the culture
media for one passage (3-4 days), to maintain human
cytokine expression [25]. All cell lines were maintained
in T-25 or T-75 culture flasks and were passaged at di-
lutions of 1:5-1:10 every 2-4 days. Low passage aliquots
of cells were thawed every two months to ensure
consistency of experiments.
Lentiviral vector preparation and ADAR1 site-directed
mutagenesis
We have previously characterized lentiviral vectors (Thermo
Scientific) for overexpression of human ADAR1 p150-IRES-
GFP [1]. For production of the catalytically-inactive ADAR1
mutated (ADAR1m) lentiviral vector, site-directed mutagen-
esis was carried out using the QuikChange II Site-Directed
Mutagenesis Kit (Agilent) according to manufacturer’s in-
structions. Mutagenic primers were designed to produce a
nucleotide substitution of A5293C, which generates an
E912A amino acid change and abolishes RNA editase activ-
ity [26]. Primers contained the desired mutation and annealto the same sequence on opposite strands of the plasmid
(FW 5′-GTCAATGACTGCCATGCAGCAATAATCTCCC
GG-3′, REV 5′-CCGGGAGATTATTGCTGCATGGCAGT
CATTGAC-3′). XLI super competent cells were trans-
formed with amplification products, after digestion
with DpnI. Colonies were screened to identify mutated
clones by DNA sequencing (Sanger sequencing, Eton
Bioscience). Lentiviruses including control vectors
(ORF) were produced according to established methods
[27], with some batches of lentivirus being produced by
the GT3 Viral Vector Core Facility (UCSD). We have
previously validated lentivirus transduction efficiency in
normal cord blood, 293 T cells and K562 cells, with an
increase of approximately five-fold overexpression of
ADAR1 transcripts confirmed by qRT-PCR analysis [1].
Transduction of human cell lines and primary cells with
lentiviral-ADAR1
For preparation of stably-transduced K562 cell lines,
50,000 wild-type (wt) K562 cells were plated into 96-well
U-bottom plates in complete culture medium and trans-
duced with lentiviral vectors expressing GFP (ORF),
ADAR1-GFP, or ADAR1m-GFP at multiplicities of infec-
tion (MOI) from 50-200. After transduction, cultures were
expanded for at least 5 passages and then processed for
FACS purification of GFP-positive cells to establish pure
stably-transduced lines. Stable expression of lentivirus-
enforced ADAR1 conferring increased transcript levels of
human ADAR1 in K562-ADAR1 cells was confirmed at
every 5 passages by qRT-PCR.
For transduction of human normal HSC and CML pro-
genitors, 50,000 CD34-selected (MACS, Miltenyi, Auburn,
CA) cells were plated in 96-well U-bottom plates in Stem-
Pro media (Life Technologies) supplemented with human
cytokines (IL-6 10 ng/mL, FLT3 ligand 50 ng/mL, SCF
50 ng/mL, and thrombopoietin 10 ng/mL) as previously
described [1,24]. Twenty-four hours later, cells were trans-
duced with lentiviral vectors (ADAR1 or ORF control,
MOI = 50-100) for up to five days. For co-culture experi-
ments, CD34-selected CP CML cells were transferred
three days after transduction (MOI = 75) to monolayers of
mouse bone marrow stromal cell cultures containing a 1:1
mixture of irradiated SL and M2 cells (50,000 total stro-
mal cells per well in 24-well plates) [27]. Primary trans-
duced cells were maintained in co-culture for five-days in
Myelocult (Stem Cell Technologies, Vancouver, Canada)
and then the total culture was harvested in lysis buffer for
RNA extraction and qRT-PCR and RESSq-PCR analyses.
Generation of a stable ADAR1 RNA editing detection
model system
For purification of stably-transduced K562 cell lines, K562
cells transduced with lentiviral-ADAR1 or ORF controls
(MOI = 50-200) were collected (minimum 1 × 106 cells),
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sorted using a FACS Aria II (Sanford Consortium Stem
Cell Core Facility) for high GFP signal to purify the
highly-transduced cell population. Purified cells were col-
lected in complete media and maintained under routine
culture conditions for K562 cells. The lentiviral-ORF and
ADAR1 vectors include a blasticidin-resistance gene, but
no significant change was observed in ADAR1 expression
in stably-transduced cell lines following selection with
blasticidin, and therefore no subsequent selection method
was used after FACS purification. For all experiments,
low-passage cells were thawed and maintained for no lon-
ger than two months in culture.
Nucleic acid isolation, reverse transcription and
quantitative RT-PCR
Cell lines, lentivirus-transduced primary hematopoietic
cells, or FACS-purified primary cells were harvested in lysis
buffer (Qiagen). RNA was purified using RNeasy extraction
kits with a DNase (Qiagen) incubation step to digest any
trace genomic DNA (gDNA) present. For RNA extraction
from cell line lysates, 1-2 × 106 cells were extracted using
RNeasy mini columns, and for primary cells, 5-10 × 104
cells were lysed and extracted using RNeasy micro col-
umns. Genomic DNA was purified from equal numbers of
cells lysed separately using the QIAamp DNA Blood Mini
Kit (Qiagen) including an RNase A incubation step to di-
gest any RNA present (Qiagen). RNA was stored at -80°C
and gDNA stored at -20°C. Immediately prior to reverse
transcription of RNA samples, nucleic acid concentrations
were quantified on a NanoDrop 2000 spectrophotometer
(Thermo Scientific), and purity was considered acceptable
if A260/A280 values were ≥1.8. For standard qRT-PCR
analysis of relative mRNA expression levels, DNA was syn-
thesized using 50 ng - 1 μg of template RNA in 20 μL reac-
tion volumes using the First-Strand SuperScript III Reverse
Transcriptase Supermix (Life Technologies) followed by in-
cubation with RNase H according to the manufacturer’s
protocol and as described previously [24]. All cDNA prod-
ucts were stored at -20°C.
Because RNA editing events often occur in pre-processed
RNA species, for cDNA preparation, three different condi-
tions were evaluated, including (1) reverse transcription
with gene-specific primers, (2) random hexamer primers
only, or (3) a supermix containing both random hexamers
and oligo-dT primers. Using cDNA prepared with all three
methods was suitable for detection of intronic regions in
cDNA prepared from DNase-digested RNA extracts, and
allowed detection of increased RNA editing in K562-
ADAR1 cells. We therefore proceeded with the standard
supermix reverse transcription method for RESSq-PCR, as
this would provide the most versatility for use of valuable
human tissue samples and would allow analysis of total
mRNA expression of other genes in the same samples.We have made every effort to adhere to the Minimal In-
formation for Publication of Quantitative Real-Time PCR
Experiments (MIQE) guidelines [28]. Primers (Additional
file 2: Table S2) were synthesized by ValueGene (San
Diego, CA) and diluted to 10 μM working dilutions in
DNase/RNase-free water. qRT-PCR was performed in du-
plicate using cDNA (1 μL reverse transcription product
per reaction) on an iCycler (Bio-Rad, Hercules, CA) using
SYBR GreenER Super Mix (Life Technologies) in 25-μL
volume reactions containing 0.2 μM of each forward and
reverse primer. Cycling conditions were as follows: 50°C
for 2 minutes, then 95°C for 8 minutes and 30 seconds,
followed by 40 cycles of 95°C for 15 seconds and 60°C for
60 seconds. Melting curve analysis was performed on each
plate according to the manufacturer’s instructions. For
standard qRT-PCR, HPRT mRNA transcript levels were
used to normalize Ct values obtained for each gene, and
relative expression levels were calculated using the 2-ddCt
method. To ensure validity of results, only Ct values <35
were used in gene expression analyses. All primer sets
were tested in a no-template control (NTC) reaction
containing only water instead of cDNA, and all gave Ct
values >35 in NTC reactions. Production of a single
amplicon of the expected size was verified for each primer
set by DNA gel electrophoresis on 2% agarose gels con-
taining ethidium bromide. For all cell line experiments,
assays were repeated at least three times using separate
RNA extracts and cDNA preparations.
RNA editing fingerprint assay
In order to implement a rapid, cost-effective and clinically
amenable method to detect a CSC-specific RNA editing
fingerprint of cancer progression, we devised an RNA edit-
ing site-specific primer design strategy that is compatible
with SYBR green qRT-PCR protocols (RESSq-PCR). Since
RNA-edited transcripts are predicted to differ from wild-
type (WT) sequences at only one nucleotide position,
detection of RNA editing by qRT-PCR requires highly
sensitive and selective primer design strategies. We have
previously developed qRT-PCR primers that specifically
recognize a gene product with a single point mutation
(JAK2 V617F [29]), and here we employed a similar ap-
proach in designing RESSq-PCR primers. Allele-specific
PCR strategies, based on positioning the 3′ base of a PCR
primer to match one variant allele, have been used for the
detection of SNPs and mutations in human gDNA or
cDNA [30], however are not routinely used in quantitative
detection of RNA single nucleotide modifications.
The RESSq-PCR assay primer design was applied to
specific cancer and stem cell-associated loci (Table 1).
Efficiency of all primer sets (Additional file 2: Table S2)
was tested using serial dilutions of K562-ADAR1 cDNA.
Primer sets were tested experimentally for human speci-
ficity and were considered to be human-specific if they
Table 1 Chromosomal coordinates and regions of RNA
editing biomarkers used for sequencing validation and
RESSq-PCR assay development
Gene Chr Position Region Reference
MDM2 12 69237534 3′UTR [1,31]
APOBEC3D 22 39415872 Intron (Alu) [1,31]
GLI1 12 57864624 Exon [32]
AZIN1 8 103841636 Exon [1,5]
SRP9 1 225976198 Intron (Alu) [1,31]
SF3B3 16 70610885 3'UTR (Alu) [1,31]
ABI1 10 27049636 Intron (Alu) [1,31]
LYST 1 235990569 Intron (Alu) [1,31]
MDM4 1 204521159 3'UTR (Alu) [1,31]
Loci (hg19 chromosomal coordinates) in bold denote sites included in the
RNA editing fingerprint assay for RESSq-PCR analysis.
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bone marrow stromal cell controls. Editing site-specific
primers for some loci (Table 1) either failed to discrim-
inate between cDNA and gDNA, or K562-ADAR1 cells
did not display increased editing by Sanger sequencing,
and therefore were not continued for assay develop-
ment. RESSq-PCR was performed in duplicate using
cDNA (1-5 μL reverse transcription product per reac-
tion) or gDNA (10-200 ng input gDNA) on an iCycler
(Bio-Rad) using SYBR GreenER Super Mix (Life Tech-
nologies) in 25-μL volume reactions containing 0.2 μM
of each forward and reverse primer. Cycling conditions
were the same as for standard qRT-PCR. Relative RNA
editing rates (Relative edit/WT RNA) were calculated
using the following calculation: 2-(Ct Edit – Ct WT).
Statistical methods
qRT-PCR data were measured as a continuous outcome
and each group was assessed for distribution. For nor-
mally distributed data, the Student’s t-test was applied to
compare differences in RNA expression and editing ratios
calculated by Sanger sequencing and RESSq-PCR, and
values are expressed as means ± SEM. Experiments were
performed in triplicate on blind-coded samples, and all
statistical analyses were performed using GraphPad Prism
(San Diego, CA).
Results
Selection and validation of aberrant RNA editing events
associated with leukemia progression
Previous whole transcriptome analysis (Figure 1A) re-
vealed widespread A-to-I RNA changes in CML LSC that
were associated with malignant progenitor reprogram-
ming typified by mis-splicing of key stem cell regulatory
transcripts in selective niches during CML progression
[1,27]. Whole transcriptome analysis of primary LSC iden-
tified 274 differentially edited sites in BC versus CP CML[1]. Candidate RNA editing loci were selected from this
dataset to validate an RNA editing fingerprint of CML pro-
gression using a site-specific RNA editing detection assay.
Eight LSC-specific loci (Table 1) were selected on the basis
of greatest average fold-change in RNA editing frequency
among significantly different sites (p < 0.005) [1]. These sites
were located within transcripts of the ubiquitin ligase hu-
man homolog of mouse double minute 2 (MDM2); the cyti-
dine deaminase apolipoprotein B mRNA editing enzyme,
catalytic polypeptide-like 3D (APOBEC3D); antizyme inhibi-
tor 1 (AZIN1); signal recognition particle 9 kDa (SRP9); spli-
cing factor 3b, subunit 3 (SF3B3); abl-interactor 1 (ABI1);
lysosomal trafficking regulator (LYST); and MDM4. Analysis
of editing rates in individual samples from our RNA-seq
dataset [1] showed increased RNA editing of MDM2, APO-
BEC3D, and AZIN1 in BC CML LSC compared with CP
progenitors (Figure 1B-D). Notably, site-specific RNA edit-
ing of AZIN1 – a regulator of tumor growth [33] – causes
exon recoding resulting in enhanced protein stability and is
associated with aggressive hepatocellular carcinoma [5]. The
majority of BC CML LSC samples displayed AZIN1 RNA
editing, while RNA editing at this site was virtually undetect-
able in CP CML progenitor cells (Figure 1D). Consistent
with these findings, Sanger sequencing of PCR products
amplified with high-fidelity DNA polymerase confirmed in-
creased APOBEC3D and AZIN1 RNA editing in BC versus
CP CML progenitors (Additional file 3: Figure S1A-D).
Development of an in vitro model of ADAR1-dependent
RNA editing
To establish a cancer-relevant model system of augmented
RNA editing, the BCR-ABL1-expressing human leukemia
cell line K562 was stably transduced with lentiviral human
ADAR1-GFP (K562-ADAR1); lentiviral ADAR1 mutant
(A5293C) that lacks deaminase activity [26] (catalytically
inactive, K562-ADAR1m); or vector open reading frame
control (K562-ORF, Figure 1E). Transduced cells express-
ing high levels of GFP were FACS-purified to establish
stable cell lines, and then expanded in vitro. ADAR1
expression was confirmed at regular intervals (approxi-
mately every 5 passages) by qRT-PCR (Figure 1F-H) using
lentiviral-specific and human-specific primers (Additional
file 2: Table S2).
RNA editing site-specific qRT-PCR (RESSq-PCR) assay
design and validation
A sensitive RNA editing fingerprint assay that employs a
site-specific quantitative PCR (RESSq-PCR) strategy was
devised to detect aberrant RNA recoding in three different
dsRNA contexts (3′UTR, intronic Alu sequences, and
coding exons). An additional known editing site within
exon 10 of the stem cell self-renewal factor GLI1 was in-
cluded because ADAR-directed RNA editing of this site
promotes transcriptional activity of GLI1 protein. The
Figure 1 Identification of an RNA editing fingerprint of malignant progenitor reprogramming, and stable ADAR1 overexpression in
K562 cells. (A) LSC purification strategy for detection of CSC-associated RNA recoding. (B-D) RNA-sequencing analysis of FACS-purified CP and BC
CML LSC [1] showing A-to-G RNA editing changes in MDM2, AZIN1 and APOBEC3D (n = 8 per group). (E) Lentiviral construct expressing human ADAR1
or a catalytically inactive form (ADAR1m). (F-H) qRT-PCR analysis of cDNA prepared from K562 lines using primers detecting ADAR1 lentivirus (F) and
total human ADAR1 (G,H) showing K562 leukemia cells stably transduced with active ADAR1 or inactive ADAR1m express high levels of ADAR1
transcripts compared with vector open reading frame (ORF) control backbone. *p < 0.05 by unpaired, two-tailed Student’s t-test.
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negative regulator of hedgehog signaling, suppressor of
fused (SUFU) [32], promoting stem cell-like behavior. For
each RNA editing site, two sets of primers were designed:
one pair detecting the WT transcript (an “A” base), and
one pair detecting the edited transcript containing a “G”
base representing inosine substitution (Figure 2A,B;
Additional file 2: Table S2). Two primer design strategies
were used to ensure highly specific detection of only A or
G(I) alleles for each editing site. The primary design
method applies the amplification refractory mutation sys-
tem (ARMS) principle [34] and the tetra-primer ARMS-
PCR web interface (Primer1 [30]) to design two unique
primer sets per editing site that would generate unique
PCR products for WT (A) or edited (G) transcripts. This
strategy employs two outer and two inner primers for
each editing site with melting temperatures ranging from
60-68°C. The forward (FW) outer and reverse (REV) outer
primers flank the editing site and can be used for Sanger
sequencing validation of each editing site, and also as a
qRT-PCR positive control to ensure that the editing region
is detectable in cDNA (Figure 2A). The 3′ ends of the FW
inner and REV inner primers match either the WT A or
edited G nucleotide, and an additional mismatch was in-
corporated two nucleotides upstream of the 3′ primer end
to enhance allelic discrimination (Figure 2A), as previouslydescribed for quantitative detection of transcripts harbor-
ing single nucleotide genomic mutations [30].
A modified secondary primer design strategy was used
in some cases where it was not possible to design primers
with similar characteristics directly upstream and down-
stream of the editing site. This strategy employs a similar
principle, however the FW inner primer sequences detect-
ing WT and edited variants are almost identical, with only
the 3′ nucleotide position differing to discriminate A or G
bases (Figure 2B). An additional mismatch was incorpo-
rated one or two nucleotides upstream of the 3′ primer
end to enhance allelic discrimination, and a common REV
primer is used for both variants (Figure 2B). Due to the in-
herent restrictions of site-specific primer design, in some
cases one set of primers was not human-specific or it was
not possible to design FW inner and REV inner primers
with similar characteristics in terms of melting temperature
and GC content, and the second strategy was applied.
RESSq-PCR primers specific for edited sites in MDM2,
APOBEC3D, GLI1 and AZIN1 distinguished G(I) bases
in cDNA from K562-ADAR1 cells, with no signal in
gDNA (Additional file 4: Figure S2A-D). In independent
experiments, RESSq-PCR assays detected increased site-
specific editing of MDM2, APOBEC3D, GLI1 and
AZIN1 (Figure 2C). Relative A-to-G(I) editing ratios in
MDM2, APOBEC3D, GLI1, and AZIN1 were increased
Figure 2 RESSq-PCR assay primer design and RNA editing fingerprint validation in stable human ADAR1-overexpressing cells.
(A,B) Primer design strategy showing RNA editing site-specific qRT-PCR (RESSq-PCR) primer design strategy (1) to selectively detect wild-type
(A) or edited (G/I) bases using the Tetra-primer amplification refractory mutation system (ARMS) principles (A). Adaptation of the RESSq-PCR
primer design strategy (2) for positions that are not compatible with the Tetra-primer ARMS method due to significant differences in GC content
directly upstream and downstream or the edited nucleotide position (B). FW= forward primer, Rev = reverse primer, Pos = positive control flanking
primers. (C) RESSq-PCR analysis of MDM2, APOBEC3D, GLI1 and AZIN1 RNA recoding in stably-transduced K562-ADAR1 cells compared with K562 wt,
K562-ORF and K562-ADAR1m lines (n = 2-4 per site). *p < 0.05 by unpaired, two-tailed Student’s t-test. (D) qRT-PCR analysis of MDM2, APOBEC3D, GLI1
and AZIN1 relative transcript expression using primers flanking each editing site in wild-type (wt) K562 (n = 5), K562-ORF (n = 5), K562-ADAR1 (n = 5)
and K562-ADAR1m (n = 3) cDNA. For calculation of transcript control levels, Ct values were normalized to qRT-PCR Ct values using human-specific
primers against HPRT.
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levels of editing detected when a mutated catalytically
inactive ADAR1 construct was stably expressed at com-
parable levels (Figure 2C). Total transcript expression
analysis of the RNA editing loci-containing regions mea-
sured by qRT-PCR using primers flanking the editing
sites showed minimal differences in expression between
groups (Figure 2D).
Sanger sequencing analysis of the stably-transduced
K562-ADAR1 cell line confirmed increased A-to-G(I)
changes in MDM2, APOBEC3D and GLI1 (Additional
file 5: Figure S3), indicating that these sites are edited in
an ADAR1-dependent manner. Notably, chromatograms
from RNA editing-rich regions often show poor quality
in heterogeneous cDNA preparations, as was observed
for MDM2 (Additional file 5: Figure S3C). This pre-
cluded quantitative analysis of RNA editing allelic ratios
by Sanger sequencing, whereas RESSq-PCR analysis re-
producibly detected increased MDM2 editing in K562-
ADAR1 cells (Figure 2C). Similar ADAR1-dependent in-
creases in G versus A nucleotides in GLI1 were detected
when comparing peak height ratios and RESSq-PCR, par-
ticularly when sequencing was performed using reverse
primers (Additional file 5: Figure S3E, G; Figure 2C).Detection of lentiviral ADAR1-induced RNA editing in
primary human cells
To investigate whether lentiviral-ADAR1 expression alters
RNA editing and can be detected by RESSq-PCR at CSC-
associated sites in primary hematopoietic stem and pro-
genitor cells, CD34+ cells were isolated from healthy hu-
man bone marrow (BM) or peripheral blood samples from
CP CML patients. After 3-5 days in vitro, normal bone
marrow cells transduced with lentiviral-ADAR1 displayed
high levels of lentivirus-derived ADAR1 compared with
ORF controls (Figure 3A,B). Sanger sequencing and
RESSq-PCR analyses showed that while variable transduc-
tion efficiency appeared to greatly influence RNA editing
rates, RNA editing activity measured by RESSq-PCR was
routinely comparable to peak height ratios calculated by
Sanger sequencing analysis (Figure 3C-F).
In CP CML hematopoietic (CD34+) cells transduced
with lentiviral-ADAR1 and co-cultured with humanized
mouse stromal cells that recapitulate the bone marrow
microenvironment [25] (Figure 4A), ADAR1 expression
levels were variable across samples, with one sample dis-
playing very high expression of ADAR1 after lentiviral-
ADAR1 transduction (Figure 4B,C). Two out of three
samples showed increased total ADAR1 expression after
Figure 3 Validation and quantification of RNA editing activity in primary bone marrow-derived hematopoietic stem and progenitor
cells transduced with lentiviral-ADAR1. CD34-selected cells from normal bone marrow (BM) samples (n = 3, average donor age = 64.3 ± 2.9 years
old) were transduced with lentiviral (lenti)-ADAR1 or vector (ORF) control. After 4 days of culture, cells were lysed and processed for qRT-PCR and
RESSq-PCR analysis. (A,B) Relative expression of lentivirus-derived (a) and total (b) ADAR1 levels in transduced BM samples (n = 3) showing increased
human ADAR1 expression in ADAR1-transduced samples, with higher levels of total ADAR1 overexpression achieved in samples BM-410 and BM-416.
(C,D) Representative Sanger sequencing analysis of high-fidelity PCR products amplified with primers flanking the APOBEC3D editing site showing in-
creased G(I) peak in lenti-ADAR1 transduced cells that displayed robust ADAR1 expression (BM-410, C). (E,F) Quantification of sequencing peak
height ratios and corresponding RESSq-PCR analysis in lenti-ORF and lenti-ADAR1 transduced BM samples.
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this correlated with increased RNA editing of APO-
BEC3D detected by RESSq-PCR (Figure 4D).Detection of a CSC-specific RNA editing fingerprint of
leukemic progression
To confirm the RNA editing fingerprint of leukemic
progression by RESSq-PCR analysis in primary samples,
FACS-purified progenitors from CP and BC CML pa-
tients (Additional file 1: Table S1) were analyzed. Re-
markably, the majority of CP samples showed low levels
of RNA editing at APOBEC3D and AZIN1 sites, while
RNA editing in BC CML LSC was more variable and
overall higher on average (Figure 5A,B), which was in
agreement with RNA-seq and Sanger sequencing-based
RNA editing analyses (Figure 1, Additional file 3: Figure
S1). Together, these data demonstrate that quantitative
RNA editing detection by RESSq-PCR provides a straight-
forward and robust measure of functional RNA editing ac-
tivity, and shed new light on potential mechanisms of
ADAR1-mediated generation of malignant progenitorsthat fuel therapeutic resistance, disease progression and
relapse in CSC-driven malignancies.
Discussion
The relative paucity of functional biomarkers that pre-
dict cancer progression represents a growing health care
concern. This has provided the impetus for developing
sensitive molecular detection systems to improve clinical
diagnosis, prognostication, and patient stratification for
clinical trials, by facilitating early detection of CSC that
drive disease progression and therapeutic resistance. Al-
ternative RNA splicing and editing of survival and self-
renewal genes has been implicated in CSC generation
and maintenance [1,24,27]. We previously reported that
RNA editing is increased in LSC during CML progres-
sion, suggesting that RNA editing activity may be an im-
portant biomarker of CML progression [1,4], with
relevance to a broad array of human malignancies. Spe-
cifically, ADAR1 was also highly expressed in pediatric
acute lymphoblastic leukemias [2], hepatocellular carcin-
oma [5], esophageal squamous cell carcinoma [7], and in
aggressive breast cancers [4]. Furthermore, a disrupted
Figure 4 In vitro humanized stromal co-culture model and RESSq-PCR analysis of primary CP CML cells transduced with lentiviral-ADAR1.
(A) Schematic diagram of humanized bone marrow stromal co-culture assay. CD34-selected hematopoietic stem and progenitor cells (HSPC) isolated
from patients with CP CML were transduced with lenti-ADAR1 or ORF control. After 3 days of culture, cells were transferred to SL/M2 mouse bone
marrow stromal monolayers for co-culture and subsequent RESSq-PCR analysis. (B,C) Increased total ADAR1 (B) and lenti-ADAR1 (C) expression in trans-
duced CP CML samples (n = 3). (D) RESSq-PCR analysis showing increased APOBEC3D RNA editing in lenti-ADAR1 transduced cells from patients with
CP CML that harbored high ADAR1 expression after transduction. Horizontal dashed lines represent comparative RNA editing activity in K562-ADAR1 and
K562-ORF cells.
Figure 5 Detection of increased RNA editing activity by RESSq-PCR analysis of primary chronic phase versus blast crisis CML progenitors.
RNA extracted from FACS-purified CD34+CD38+Lin- primary CML progenitors was analyzed by RESSq-PCR to validate the RNA editing fingerprint of
leukemic progression. (A) RESSq-PCR analysis detecting increased RNA editing in APOBEC3D in purified BC CML LSC versus CP progenitors. (B) RESSq-
PCR analysis detecting increased RNA editing in AZIN1 in purified BC CML LSC versus CP progenitors. Horizontal dashed lines represent comparative
RNA editing activity in K562-ADAR1 and K562-ORF cells.
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for patients with hepatocellular carcinoma [6].
Next-generation technologies have enabled RNA and
DNA sequencing of rare cell populations, providing
insights into the gene networks and central pathways
that contribute to cancer initiation, progression and
therapeutic resistance. While a recent report described
a multiplex PCR method to quantify RNA allelic ratios
by sequencing at numerous sites [35], one obstacle to
such analytical strategies is that high-throughput se-
quencing often must be performed by external rather
than local laboratories. The RNA editing fingerprint
assay described here can be performed using routine
laboratory reagents and showed improved sensitivity
over Sanger sequencing and traditional chromatogram
analysis. Thus, RESSq-PCR, developed as an array-
based technology detecting a CSC-specific RNA edit-
ing fingerprint of malignant reprogramming, could
provide a rapid clinical assay for early detection of
cancer progression and prognostication.
One of the most widely used traditional methods to de-
tect RNA editing activity at specific sites is Sanger sequen-
cing, however this technique can only detect RNA editing
at sites where greater than 5-20% of transcripts are edited
[36] and is best used to measure qualitative differences
[37]. Because even low RNA editing rates may be func-
tionally relevant to cancer [5], and differentially-edited loci
in CML LSC show <5% editing in CP CML progenitors by
RNA-seq [1], Sanger sequencing does not provide a suffi-
ciently sensitive method for quantifying disease-associated
RNA editing. A handful of strategies have been described
to detect site-specific variant alleles by using WT (A) spe-
cific qRT-PCR primers [38] or custom Taqman probes
[36], however the RESSq-PCR assay provides the first
qRT-PCR strategy to detect edited human transcripts as
biomarkers for CSC detection and disease stratification.
Notably, RESSq-PCR can be used to detect endogenous
RNA editing, while alternative strategies to detect RNA
editing activity require transfection with exogenous sub-
strates and reporter genes [39,40]. Although reporter tools
are practical in screening assays to identify ADAR activa-
tors or inhibitors [40], minimal cellular manipulation is es-
sential for future studies of the functional consequences of
RNA editing modulation.
Notably, this straightforward nucleotide editing fin-
gerprint assay could also be applied to detect cytidine
deamination in RNA or DNA by APOBEC family pro-
teins, which may contribute to DNA mutagenesis in hu-
man cancer [41-43]. Additionally, altered RNA editing
was recently reported in neurodegenerative disease [44],
and thus, methods for clinical detection of abnormal
RNA editing could have wide-ranging applications for
the diagnosis and treatment of a variety of degenerative,
developmental and malignant disorders.In the present study we noted that there may be some
site-specific variability in RNA editing across patient sam-
ples and therefore in clinical applications it will be advan-
tageous to evaluate multiple editing sites simultaneously
using the RNA fingerprint assay. For example, sample BC-
02 showed moderate editing at the APOBEC3D site by
RESSq-PCR, but editing of AZIN1 was below the qRT-
PCR detection threshold (Ct value >35) (Figure 5). Simi-
larly, in our previous RNA-seq study (Figure 1B-D), at
some sites a subset of BC samples showed low editing ra-
tios, or editing activity within the range of CP samples,
but showed higher editing rates at other sites. Thus, we
predict that the prognostic significance of RNA editing ac-
tivation may be in detection of one or more CSC-
associated sites displaying increased editing rates.
Indeed, comparison of the RNA editing ratios in individ-
ual cases at each LSC-associated site determined previously
by whole transcriptome sequencing revealed that while
editing of AZIN1 was relatively low by RNA-seq in cases
BC-02 and BC-08 (consistent with the RESSq-PCR results),
these cases were among the ones that showed highest edit-
ing rates in MDM2 [1]. These site-specific differences are
likely related to differential transcript stability after post-
transcriptional processing [16], and highlight the import-
ance of using a validated panel of RNA editing biomarkers
to measure RNA editing activity clinically, rather than a
single biomarker or ADAR1 expression levels alone.
Future studies evaluating larger cohorts of cancer pa-
tients, with comprehensive clinical annotation of patient
treatment status and disease outcomes, will provide fur-
ther insights into the relationship between aberrant RNA
editing and risk for disease progression. Additionally, we
hypothesize that RNA editing activity may be influenced
by differing treatment status at the time of sample collec-
tion (e.g. hydroxyurea versus imatinib) and could also pro-
vide prognostic information related to risk for acquisition
of drug resistance. Thus, assessment of sequential patient
samples before and after treatment or disease progression
will allow precise determination of the RNA editing levels
that correlate with poorer prognosis in a variety of blood
cancers and other CSC-driven malignancies.
Conclusions
Recent evidence indicates that ADAR-directed RNA edit-
ing represents a novel mechanism of disease progression
and a promising therapeutic target for diverse human can-
cers. Malignant RNA editing programs represent an unex-
plored resource for biomarker development, and the
development of an RNA editing fingerprint assay demon-
strates the application of novel findings from high-
throughput sequencing and bioinformatics studies [1,27]
to validate unique CSC-specific molecular signatures of
cancer progression. Furthermore, the RESSq-PCR RNA
editing diagnostic platform provides an innovative method
Crews et al. Journal of Translational Medicine  (2015) 13:52 Page 11 of 12for testing specificity of candidate CSC-targeted therapeu-
tics to inhibit RNA editing, and could serve as an inform-
ative companion diagnostic for clinical trials. In summary,
this study demonstrates the rapid translation of next-
generation sequencing data into a functionally relevant tool
for detection of an RNA editing fingerprint of malignant
progenitor reprogramming that could identify patients at
risk for cancer progression and therapeutic resistance.
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